BOCA RATON, Fla., October 8, 2026 /OrthoSpineNews/ – SurGenTec®, a privately held medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that it has entered into an exclusive license agreement with Allevion Medical for its patented Vantage™ spinal decompression technology.
SurGenTec® Enters Exclusive License Agreement with Allevion Medical for Vantage™ Spinal Decompression System
2 min read Premium comments
lumbar decompressionSurGenTec#vantageAllevion Medicalexclusive license agreement
Under the terms of the agreement, SurGenTec® has secured exclusive rights to Allevion Medical’s Vantage™, a fully disposable, sterile system designed to simplify and enhance minimally invasive lumbar decompression procedures. The system addresses pain associated with hypertrophic bone growth, a common contributor to lumbar spinal stenosis. Vantage™ allows physicians to perform a laminotomy or laminectomy through a patented minimally invasive approach while directly visualizing anatomical structures.
Vantage™ enables targeted decompression through a patented approach that combines precision with procedural control. It follows an intuitive, reproducible workflow (locate, visualize, decompress) that helps physicians perform the procedure with greater consistency and efficiency. This structured approach supports procedural safety while enabling surgeons to efficiently remove hypertrophic bone from the lamina and facet joints that may contribute to spinal canal narrowing.
Traditional decompression procedures often require larger incisions and bulky instrumentation to retract tissue, which may increase the risk of scar tissue formation, prolonged recovery, and chronic pain. Other minimally invasive systems focus primarily on soft tissue removal, such as the ligamentum flavum alone, which may not provide sufficient decompression when hypertrophic bone is a primary contributor to stenosis.
A key differentiator of Vantage™ is its direct visualization capability, supported by single-use integrated illumination that allows physicians to visualize the targeted anatomy throughout the procedure. This feature enhances procedural control while supporting greater precision and safety.
Key highlights of Vantage™ include:
Fully disposable, sterile system requiring no additional instruments or sterile processing
Reproducible, step-based workflow designed to support procedural safety and efficiency
Minimally invasive approach designed to limit tissue disruption
Precision tools engineered for depth-controlled bone resection
Single-use integrated illumination enabling direct visualization of the surgical site
Protective guards designed to help reduce the risk of damage to delicate structures
Vantage™ provides physicians with a streamlined and reliable solution for treating lumbar spinal stenosis. Its single-use design, structured workflow, and integrated visualization capabilities help establish a new standard for efficiency, control, and consistency in spinal decompression procedures.
“This exclusive license agreement expands SurGenTec®’s portfolio of innovative, minimally invasive spine solutions and aligns with our commitment to delivering advanced technologies that improve procedural efficiency and patient outcomes,” said Matt Marta, VP of Sales at SurGenTec®. “Vantage™ complements our existing offerings by providing surgeons with a fully disposable system designed for precision and ease of use in treating lumbar spinal stenosis.”
About SurGenTec®
SurGenTec® is a privately held medical device company based in Boca Raton, Florida, specializing in innovative technologies for orthopedic and spine treatments. The company develops and manufactures solutions focused on minimally invasive approaches, including facet fixation systems, synthetic biologics, bone graft delivery systems, and sacroiliac joint fusion technologies. SurGenTec® is dedicated to advancing patient care through continuous innovation and is expanding its presence in both domestic and international markets. For more information, visit www.surgentec.com/vantage.
Contacts
SurGenTec® Customer Service
(561) 990-7882
customerservice@surgentec.com
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
SurGenTec secured an exclusive license for Allevion Medical's Vantage™ spinal decompression system, strategically expanding its minimally invasive spine portfolio. This fully disposable, sterile system targets lumbar spinal stenosis, offering direct visualization and a reproducible workflow. It aims to enhance procedural efficiency and patient outcomes, potentially setting a new standard in the market by addressing limitations of traditional and existing minimally invasive approaches.
- The agreement enhances SurGenTec's market position in minimally invasive spine solutions by adding a differentiated, disposable system.
- Vantage™'s features like direct visualization and a streamlined workflow aim to drive adoption by improving procedural safety and efficiency.
PhD Lens: Clinical and outcomes impact
SurGenTec licensed the Vantage™ spinal decompression system, designed for minimally invasive laminotomy or laminectomy. This sterile, disposable system targets hypertrophic bone growth in lumbar spinal stenosis, utilizing precision tools for depth-controlled bone resection. Integrated illumination provides direct visualization, enhancing procedural control and safety by allowing surgeons to efficiently remove bone from the lamina and facet joints.
- The system's mechanism involves targeted removal of hypertrophic bone from lamina and facet joints, addressing a primary cause of spinal canal narrowing.
- Key safety features include direct visualization via integrated illumination and protective guards, designed to minimize tissue disruption and enhance precision.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.